These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 29300334)

  • 1. Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets.
    Schmid-Alliana A; Schmid-Antomarchi H; Al-Sahlanee R; Lagadec P; Scimeca JC; Verron E
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29300334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic targets for cancer bone metastasis.
    Krzeszinski JY; Wan Y
    Trends Pharmacol Sci; 2015 Jun; 36(6):360-73. PubMed ID: 25962679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New trends in the treatment of bone metastasis.
    Keller ET; Dai J; Escara-Wilke J; Hall CL; Ignatoski K; Taichman RS; Keller J
    J Cell Biochem; 2007 Dec; 102(5):1095-102. PubMed ID: 17955492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the metastatic niche: targeting the microenvironment.
    Guise T
    Semin Oncol; 2010 Oct; 37 Suppl 2():S2-14. PubMed ID: 21111245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.
    Hiraga T
    Expert Opin Investig Drugs; 2016; 25(3):319-34. PubMed ID: 26778342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of bone metastasis.
    Pantano F; Iuliani M; Zoccoli A; Fioramonti M; De Lisi D; Fioroni I; Ribelli G; Santoni M; Vincenzi B; Tonini G; Santini D
    Expert Opin Emerg Drugs; 2015; 20(4):637-51. PubMed ID: 26113304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
    Park SH; Keller ET; Shiozawa Y
    Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
    Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F
    Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming immunosuppression in bone metastases.
    Reinstein ZZ; Pamarthy S; Sagar V; Costa R; Abdulkadir SA; Giles FJ; Carneiro BA
    Crit Rev Oncol Hematol; 2017 Sep; 117():114-127. PubMed ID: 28600175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer bone metastases: pathogenesis and therapeutic targets.
    Brook N; Brook E; Dharmarajan A; Dass CR; Chan A
    Int J Biochem Cell Biol; 2018 Mar; 96():63-78. PubMed ID: 29309917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer.
    Quayle L; Ottewell PD; Holen I
    Curr Cancer Drug Targets; 2015; 15(6):469-80. PubMed ID: 25968899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases.
    Sottnik JL; Dai J; Zhang H; Campbell B; Keller ET
    Cancer Res; 2015 Jun; 75(11):2151-8. PubMed ID: 25855383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular biology of bone metastases].
    Doll A; García M; Rigau M; Olivan M; Montes M; Sequeiros T; Llaurado M; Colás E; Reventós J; Morote J
    Arch Esp Urol; 2013 Jun; 66(5):463-74. PubMed ID: 23793764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.
    Chirgwin JM; Guise TA
    J Cell Biochem; 2007 Dec; 102(6):1333-42. PubMed ID: 17907152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agents targeting prostate cancer bone metastasis.
    Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapies in bone metastasis.
    Clément-Demange L; Clézardin P
    Curr Opin Pharmacol; 2015 Jun; 22():79-86. PubMed ID: 25935860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
    Zhao Q; Luo F; Ma J; Yu X
    Curr Cancer Drug Targets; 2015; 15(8):716-25. PubMed ID: 26119014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
    Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.